MiR-101-3p Suppresses Progression of Cervical Squamous Cell Carcinoma by Targeting and Down-Regulating KPNA2

被引:8
作者
Wang, Hong [1 ]
Xiao, Rongxin [1 ]
Yang, Biao [1 ]
机构
[1] Funing Peoples Hosp, Funing, Jiangsu, Peoples R China
关键词
microRNA-101-3p; KPNA2; cervical squamous cell carcinoma; proliferation; migration; invasion; CANCER; PROLIFERATION; ALPHA-2;
D O I
10.1177/15330338211055948
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective We explored mechanism of microRNA-101-3p/Karyopherin alpha 2 (KPNA2) axis in cervical squamous cell carcinoma. Methods: Bioinformatics methods were applied to identify genes for the study. Cell functional assays were implemented to examine the role of the genes in malignant progression of cervical squamous cell carcinoma. Targeting relationship between genes was verified by dual-luciferase assay. Results: MicroRNA-101-3p was lowly expressed in cervical squamous cell carcinoma, while KPNA2 was highly expressed. Dual-luciferase assay identified direct targeting relationship between microRNA-101-3p and KPNA2. Functional assays manifested that highly expressed microRNA-101-3p suppressed cervical squamous cell carcinoma cell growth by targeting KPNA2. Conclusion: Overall, microRNA-101-3p/KPNA2 axis can play an important part in progression of cervical squamous cell carcinoma.
引用
收藏
页数:7
相关论文
共 20 条
[1]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[2]   Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin α2 as a potential novel prognostic marker in breast cancer [J].
Dahl, Edgar ;
Kristiansen, Glen ;
Gottlob, Kathrin ;
Klaman, Irina ;
Ebner, Elke ;
Hinzmann, Bernd ;
Hermann, Klaus ;
Pilarsky, Christian ;
Duerst, Matthias ;
Klinkhammer-Schalke, Monika ;
Blaszyk, Hagen ;
Knuechel, Ruth ;
Hartmann, Arndt ;
Rosenthal, Andre ;
Wild, Peter J. .
CLINICAL CANCER RESEARCH, 2006, 12 (13) :3950-3960
[3]   Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors [J].
He, Xia ;
Li, Jian-Pei ;
Liu, Xiao-Hua ;
Zhang, Jing-Ping ;
Zeng, Qiu-Yao ;
Chen, Hao ;
Chen, Shu-Lin .
JOURNAL OF CANCER, 2018, 9 (10) :1877-1884
[4]   Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma [J].
He, Yue ;
Zhao, Hui ;
Li, Xing-Ming ;
Yin, Cheng-Hong ;
Wu, Yu-Mei .
GENE, 2019, 690 :30-37
[5]   KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a [J].
Huang, L. ;
Wang, H-Y ;
Li, J-D ;
Wang, J-H ;
Zhou, Y. ;
Luo, R-Z ;
Yun, J-P ;
Zhang, Y. ;
Jia, W-H ;
Zheng, M. .
CELL DEATH & DISEASE, 2013, 4 :e745-e745
[6]   Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis [J].
Lee, Kwang-Beom ;
Shim, Seung-Hyuk ;
Lee, Jong-Min .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (04)
[7]   LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression [J].
Liang, Haihai ;
Yu, Tong ;
Han, Yue ;
Jiang, Hua ;
Wang, Chengyu ;
You, Tianyi ;
Zhao, Xiaoguang ;
Shan, Huitong ;
Yang, Rui ;
Yang, Lida ;
Shan, Hongli ;
Gu, Yunyan .
MOLECULAR CANCER, 2018, 17
[8]   MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4 [J].
Lin, Jiaxin ;
Zhang, Lan ;
Huang, He ;
Huang, Yongwen ;
Huang, Long ;
Wang, Jianhua ;
Huang, Shuting ;
He, Li ;
Zhou, Yun ;
Jia, Weihua ;
Yun, Jingping ;
Luo, Rongzhen ;
Zheng, Min .
ONCOTARGET, 2015, 6 (27) :23793-23806
[9]   mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK [J].
Liu, Peng ;
Ye, Feng ;
Xie, Xinhua ;
Li, Xing ;
Tang, Hailin ;
Li, Shuaijie ;
Huang, Xiaojia ;
Song, Cailu ;
Wei, Weidong ;
Xie, Xiaoming .
ONCOTARGET, 2016, 7 (23) :35188-35198
[10]   Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer [J].
Lu, Hai-Min ;
Yi, Wan-Wan ;
Ma, Yu-Shui ;
Wu, Wei ;
Yu, Fei ;
Fan, Heng-Wei ;
Lv, Zhong-Wei ;
Yang, Hui-Qiong ;
Chang, Zheng-Yan ;
Zhang, Chao ;
Xie, Wen-Ting ;
Jiang, Jun-Jian ;
Song, Ying-Chun ;
Chai, Li ;
Jia, Cheng-You ;
Lu, Gai-Xia ;
Zhong, Xiao-Jun ;
Hou, Li-Kun ;
Wu, Chun-Yan ;
Shi, Min-Xin ;
Liu, Ji-Bin ;
Fu, Da .
ONCOLOGY LETTERS, 2018, 16 (06) :7048-7056